Numerous studies have also indicated that inhibition of CXCR4 by small-molecule inhibitors (AMD3100/plerixafor; AMD3465) leads to peripheral mobilization of AML cells and renders them sensitive to chemotherapy (145–147). This evidence concerns the gene CXCR4 and acute myeloid leukemia.